Unituxin

Indications and uses
Unituxin is a GD2- binding monoclonal antibody suitable for use with granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin -2(IL-2) and 13- cis-retinoic acid (RA). It is a first-line multi-drug, and it can achieve at least partial remission before multi-mode treatment for neuroblastoma children with high risk.

Dosage and administration method
17.5 mg/m2/day was used as a diluted intravenous infusion lasting 10 to 20 hours for 4 consecutive days, with a total of 5 courses of treatment.

Dosage forms and specifications
Injection: 17.5 mg/5 mL(3.5 mg/mL) in a single-use vial.

Warnings and precautions
⑴ Capillary leakage syndrome and hypotension: patients need to be pre-hydrated and closely monitored during treatment. Depending on the severity, the infusion rate is slowed down by interruption, or terminated permanently.
⑵ Infection: Discontinue until the systemic infection is solved.
⑶ Ophthalmology diseases: the pupil with dilated pupils is slow to reflect light or other visual obstacles are interrupted, and the recurrent eye diseases or blindness are permanently terminated.
⑷ Bone marrow suppression: Monitor the peripheral blood cell count during Unituxin treatment.
5. Electrolyte abnormality: closely monitor serum electrolytes.
(6) atypical hemolytic uremic syndrome: permanently terminate Unituxin and start supporting treatment.
(7) Fetal toxicity: it may cause fetal harm. Advise women with reproductive potential on the potential risks to the fetus and use effective contraception.

adverse effect
The most common adverse drug reactions (≥ 25%) are pain, fever, thrombocytopenia, lymphopenia, transfusion reaction, hypotension, hyponatremia, alanine aminotransferase increase, anemia, vomiting, diarrhea, hypokalemia, capillary leakage syndrome, neutropenia, urticaria, hypoalbuminemia, aspartate aminotransferase increase, and hypocalcemia. The most common serious adverse reactions (≥ 5%) are infection, infusion reaction, hypokalemia, hypotension, pain, fever, and capillary leakage syndrome.